This concern provided a rationale for the phase 3 CREATE-X trial (UMIN000000843), which tested whether adjuvant capecitabine improves OS for patients with HER2-negative breast cancer who failed to attain pCR with NAC54. This evidence concerns the gene ERBB2 and breast cancer.